Penile Traction for Penile Lengthening

Penile lengthening through traction is a non-surgical medical approach that uses calibrated mechanical force applied over extended periods to stimulate permanent tissue growth in the penile shaft. For men researching how to increase penis size through evidence-based methods, penile traction therapy is the only non-surgical approach supported by more than 15 peer-reviewed clinical studies involving over 1,000 patients.

Penile traction therapy achieves lengthening through a biological process called mechanotransduction — the cellular response to sustained mechanical force that triggers new tissue formation at the molecular level. Unlike pills, supplements, or manual exercises that lack clinical evidence, traction-based lengthening produces measurable, permanent structural changes confirmed by urological research.

The biological mechanism behind traction-based penile lengthening operates within the tunica albuginea — the dense fibrous sheath surrounding the erectile chambers of the penis. When a penile traction device applies sustained force along the penile axis, the mechanical stimulus activates cellular signaling pathways that promote cell division, collagen synthesis, and new blood vessel formation.

Chung and Brock (2013) documented the histological basis for traction-induced tissue growth: sustained traction produces "reorganization and remodelling of collagen fibres into uniform densely packed fibrils parallel to the axis of mechanical strain." This finding confirms the biological mechanism underlying all clinical lengthening outcomes.

The process of tissue expansion under traction follows the same biological principle used in reconstructive surgery, where controlled mechanical force generates new tissue without grafts or implants. In penile traction therapy, this mechanotransduction response produces measurable, permanent elongation of the penile shaft in both flaccid and erect states.

Clinical studies consistently report that gains achieved through traction therapy are maintained at follow-up assessments conducted months after treatment cessation — confirming that the tissue growth is structural, not temporary.

Clinical evidence for traction-based penile lengthening comes from a robust body of peer-reviewed research spanning more than fifteen years of urological investigation. The 2023 systematic review and meta-analysis by Almsaoud, Safar, and Alshahrani, published in Translational Andrology and Urology, represents the strongest available evidence.

The Almsaoud meta-analysis pooled data from twelve clinical studies involving over 1,000 patients to calculate a weighted mean length gain of 1.9 cm (0.75 inches) with penile traction therapy. Treatment adherence across the pooled studies reached 82%, and patient satisfaction rates exceeded 80%.

Gontero and colleagues at the University of Turin published one of the earliest prospective studies on penile traction therapy in BJU International (2009). The study enrolled 21 men, with 16 completing the full protocol using the Andro-Penis traction device at 600–1,200 grams of force for 4–6 hours daily over 6 months.

Gontero et al. reported a mean flaccid length gain of 2.3 cm and a stretched length gain of 1.7 cm at 6 months. No serious adverse events were reported across the study population. Follow-up assessments showed no regression of length gains in the six months after treatment ended — establishing that traction-based lengthening produces permanent structural changes.

Nikoobakht and colleagues, publishing in the Journal of Sexual Medicine (2011), confirmed these findings with a cohort of 23 men using penile traction for 3 months. Nikoobakht et al. reported gains of 1.7 cm (0.67 inches) in both flaccid and stretched penile length — a statistically significant improvement (p<0.05).

Flaccid penile length in the Nikoobakht study increased from a mean of 8.8 cm (3.5 inches) to 10.5 cm (4.1 inches), while stretched penile length increased from 11.5 cm (4.5 inches) to 13.2 cm (5.2 inches).

The randomized controlled trial by Joseph and colleagues, published in the Journal of Sexual Medicine (2020), enrolled 110 participants and demonstrated that 94% achieved increased penile length with traction therapy. Joseph et al. reported mean length gains of 1.6 cm (0.6 inches), with some participants achieving gains of up to 2.3 cm (0.9 inches) with consistent daily use.

The high success rate — 94% of participants achieving measurable lengthening — confirmed the reliability of the mechanotransduction response across diverse patient populations.

The post-prostatectomy randomized controlled trial by Toussi, Ziegelmann, and Yang, published in the Journal of Urology (2021), provided the strongest controlled evidence for traction-based lengthening. Among 82 men randomized to traction therapy or standard care, the traction group gained an average of 1.6 cm (0.6 inches) versus 0.3 cm (0.1 inches) in the control group — a statistically significant difference (p<0.01).

Patient satisfaction in the Toussi study was exceptionally high: 87% would repeat the therapy and 93% would recommend penile traction to other men. The Toussi trial also documented improved erectile function scores alongside length gains, demonstrating benefits beyond lengthening alone.

Clinical Study Summary

Measurement standardization across traction studies relies on stretched penile length (SPL) — a clinical measurement performed by extending the penis to maximum length without erection, measured from the pubic bone to the tip of the glans.

Stretched penile length correlates closely with erect penile length and provides a reproducible measurement standard for comparing outcomes across clinical trials. Both the Almsaoud meta-analysis and the Toussi randomized controlled trial used SPL as the primary outcome measure, ensuring scientific rigor in reported lengthening outcomes.

Penile traction therapy produces a mean length gain of 1.3–2.3 cm (0.5–0.9 inches) over 3–6 months of daily use at 4–6 hours per day. The 2023 meta-analysis by Almsaoud and colleagues, published in Translational Andrology and Urology, confirmed an average gain of 1.9 cm (0.75 inches) across twelve pooled clinical studies involving over 1,000 patients.

These figures represent clinically measured averages — individual outcomes vary based on treatment compliance, daily wear duration, baseline anatomy, and device quality.

Flaccid penile length gains from traction therapy tend to be more pronounced than stretched length gains. Gontero et al. reported 2.3 cm flaccid gain and 1.7 cm stretched gain at 6 months, while Nikoobakht et al. reported identical 1.7 cm (0.67 inches) improvements in both flaccid and stretched measurements at 3 months.

Some clinical participants achieved gains exceeding 2.0 cm (0.8 inches) with extended, consistent use. The Joseph et al. randomized controlled trial documented gains of up to 2.3 cm (0.9 inches) in the most compliant participants over 6 months.

Factors That Affect Lengthening Outcomes

Daily wear duration is the single strongest predictor of lengthening outcomes. Clinical protocols across published studies prescribe 4–6 hours of daily traction device use. The Nikoobakht study protocol included up to 9 hours daily in the extended phase, correlating with the higher 1.7 cm gain achieved at 3 months.

Shorter daily wear durations produce proportionally smaller gains, as the mechanotransduction response requires sustained stimulus to maintain cellular proliferation.

Treatment duration determines the cumulative lengthening effect. Studies ranging from 3 months (Nikoobakht et al.) to 6 months (Gontero et al., Toussi et al., Joseph et al.) show progressively greater gains with longer treatment periods.

The Almsaoud meta-analysis confirmed that longer treatment protocols consistently produce larger average gains across all pooled study populations.

Compliance consistency matters more than isolated long sessions. The Almsaoud meta-analysis reported 82% treatment adherence across pooled studies, and the highest-performing studies achieved adherence rates above 85%. Consistent daily use triggers repeated mechanotransduction cycles that compound over weeks and months.

Device quality directly affects both outcomes and compliance. Medical-grade penile traction devices that deliver calibrated, measurable force across the full tension range (900–2,800 grams / 8.8–27.5 Newtons) ensure the traction stimulus falls within the clinically validated therapeutic window.

Poorly manufactured devices that cannot maintain consistent tension or lack adequate comfort systems result in lower compliance rates and inferior outcomes.

Penile lengthening surgery and penile traction therapy represent the two primary approaches to increasing penile length, differing fundamentally in invasiveness, risk profile, cost, and evidence base. Surgical penile lengthening typically involves division of the suspensory ligament (ligamentolysis) to release the internal portion of the penile shaft, sometimes combined with dermal fat grafts or silicone implants.

Penile traction therapy achieves lengthening through non-invasive, biological tissue growth stimulated by sustained mechanical force — eliminating the surgical risks of scarring, nerve damage, and potential shortening.

Surgical penile lengthening carries significant risks that penile traction therapy avoids entirely. Ligamentolysis can result in penile instability during erection due to loss of suspensory ligament support. Post-surgical scarring may produce visible deformity or palpable nodules at the surgical site.

Nerve damage during the procedure can cause reduced penile sensation — a complication with no available repair. In some cases, scar contracture after penile lengthening surgery causes the penis to become shorter than the pre-operative baseline — the opposite of the intended outcome.

The cost differential between surgical and non-surgical penile lengthening is substantial. Penile lengthening surgery typically costs $5,000–$20,000 or more depending on the surgeon, facility, and geographic location — often not covered by insurance because the procedure is classified as cosmetic.

Penile traction therapy with an FDA-registered medical device represents a one-time investment that can be used at home under medical guidance, offering comparable or superior lengthening outcomes at a fraction of the cost.

The Hehemann et al. (2019) review from the Mayo Clinic, published in the context of penile rehabilitation, concluded that penile traction therapy represents the most evidence-based non-surgical approach to penile lengthening, with a favorable risk-to-benefit ratio compared to surgical alternatives.

Moncada and colleagues (2019), publishing in Therapeutic Advances in Urology, further validated penile traction as effective for both Peyronie's disease management and penile shortening reversal — positioning traction therapy as a first-line approach before surgical consideration. For men experiencing penile shortening after prostatectomy or as part of aging, traction therapy offers the only non-surgical, clinically validated method to restore lost length.

Penile traction therapy for lengthening follows a progressive protocol that gradually increases tension force and daily wear duration over a 3–6 month treatment period. Clinical studies confirm that progressive tension application produces optimal lengthening outcomes while maintaining patient comfort and treatment adherence.

The treatment protocol outlined below reflects the clinical guidelines established across published penile traction research.

Phase 1: Adaptation (Weeks 1–2)

Begin penile traction at the lowest comfortable tension setting — approximately 600–900 grams (5.9–8.8 Newtons) — for 2–3 hours per day. The adaptation phase allows penile tissue to acclimate to the sustained mechanical stimulus without exceeding comfort thresholds.

Shorter initial sessions build familiarity with the device and establish the daily habit that is essential for long-term treatment success. No measurable lengthening is expected during the adaptation phase.

Phase 2: Progressive Loading (Weeks 3–8)

Increase traction force gradually to 900–1,500 grams (8.8–14.7 Newtons) and extend daily wear duration to 4–6 hours. The progressive loading phase initiates the mechanotransduction response at therapeutic intensity levels.

First measurable changes in stretched penile length typically appear during weeks 4–8 of consistent daily traction use. Clinical studies by Nikoobakht et al. and Gontero et al. both documented early tissue response indicators within this timeframe.

Phase 3: Full Therapeutic Protocol (Months 3–6)

Maintain daily traction at 1,200–2,800 grams (11.8–27.5 Newtons) for 4–6 hours per day during the full therapeutic phase. The maximum clinically validated force range for penile traction therapy extends to 2,800 grams (27.5 Newtons) — the upper limit of the SizeGenetics device calibration.

The full therapeutic protocol produces the cumulative mechanotransduction stimulus that generates the 1.3–2.3 cm (0.5–0.9 inches) length gains documented in peer-reviewed clinical studies.

Measurement tracking throughout the traction protocol requires consistent use of stretched penile length (SPL) as the standard measurement method. Measure from the pubic bone to the glans tip while extending the penis to maximum non-erect length.

Record measurements at 2-week intervals using the same technique and conditions. Clinical studies use SPL because the measurement is reproducible and correlates closely with erect penile length — providing the most accurate tracking of lengthening progress over the treatment period.

Consultation with a healthcare provider before beginning any penile traction therapy program ensures the protocol is appropriate for individual anatomy and health status. Medical supervision is particularly important for men with Peyronie's disease, prior penile surgery, or cardiovascular conditions that may affect penile tissue response to sustained traction force.

SizeGenetics is an FDA-registered Class II medical device manufactured by Danamedic ApS in Kongens Lyngby, Denmark. Invented in 1994 by plastic surgeon Dr. Jørn Ege Siana and entrepreneur Jes Bech Müller, SizeGenetics was the first penile traction device brought to market — establishing the category that more than 15 peer-reviewed clinical studies have since validated for penile lengthening.

Danamedic has sold more than 500,000 penile traction devices across five brands since the original 1994 invention, making the company the most experienced manufacturer of penile traction technology in the world.

The SizeGenetics device delivers calibrated traction force across a range of 900–2,800 grams (8.8–27.5 Newtons) — spanning the full therapeutic window validated in clinical penile lengthening studies. The 58-way Multi-Axis Comfort Technology addresses the primary barrier to treatment success: comfort during extended daily wear.

Clinical meta-analyses consistently identify treatment adherence as the strongest predictor of lengthening outcomes. The Almsaoud 2023 meta-analysis reported 82% adherence across pooled studies, while higher-adherence protocols produced proportionally greater length gains. The SizeGenetics comfort system is engineered specifically to maximize compliance across the 4–6 hour daily wear protocol.

FDA registration (Registration #3005401991) confirms that SizeGenetics meets the regulatory requirements for medical devices sold in the United States. The device holds CE Mark certification under the European Union Medical Device Regulation, meeting the safety and performance standards required for medical devices distributed across European markets.

These regulatory credentials distinguish SizeGenetics from unregulated consumer products marketed without clinical validation or quality manufacturing standards.

Dr. Jørn Ege Siana, plastic surgeon and co-inventor of the penile traction device, developed the original SizeGenetics design based on the established surgical principle of tissue expansion under controlled mechanical force. The device has been recommended by medical professionals across multiple specialties — including Dr. Finn Worm Knudsen, a specialist plastic surgeon who endorses traction therapy for tissue lengthening, and Dr. Michael Carter, a clinical psychologist who recognizes the psychological benefits of evidence-based penile lengthening for men experiencing size-related anxiety.

The medical authority behind SizeGenetics extends beyond its inventors — the device has been used in clinical practice by urologists including those at the Mayo Clinic (Toussi et al., 2021) and medical centers across Europe, North America, and Asia.

The SizeGenetics device comes with a 6-month money-back guarantee, reflecting the manufacturer's confidence in the clinically validated lengthening outcomes achieved through consistent traction therapy use.

Penile traction therapy is the only non-surgical method validated by peer-reviewed clinical evidence for measurable, permanent lengthening. The following pages explore the underlying science, safety data, treatment protocols, and clinical outcomes in detail.